Quick Takeaways
- BB BIOTECH AG filed SCHEDULE 13G/A for Esperion Therapeutics, Inc. Common Stock (ESPR).
- Disclosed ownership: 4.9%.
- Date of event: 04 Mar 2025.
BB BIOTECH AG - 04 Mar 2025 SCHEDULE 13G/A Report for Esperion Therapeutics, Inc. Common Stock (ESPR)
- Filing Manager
- BB BIOTECH AG
- Reporting Manager
- BB Biotech AG
- Symbol
- ESPR
- Shares outstanding
- 197,848,943 shares
- Disclosed Ownership
- 9,694,064 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 10 Mar 2025, 11:12:30 UTC
- Date of event
- 04 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BB BIOTECH AG disclosed 4.9% ownership in Esperion Therapeutics, Inc. Common Stock (ESPR) on 04 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 10 Mar 2025, 11:12.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BB Biotech AG | 4.9% | 9,694,064 | 0 | 9,694,064 | /s/ Martin Gubler | Martin Gubler/Signatory Authority | |
| Biotech Target N.V. | 4.9% | 9,694,064 | 0 | 9,694,064 | /s/ Jan Bootsma | Jan Bootsma/Signatory Authority |